Perhaps Coppashaft has additional information, but from what is published by the FDA about the upcoming meetings he referenced, Avita's ReCell does not seem to be on the agenda for either the 17th or 18th Oct. meetings. Two other company's drugs are listed for discussion, not ReCell.
For the rest of the year, here is a thumbnail sketch of the upcoming topics of the public meetings.
October October 3 - Science Board to the FDA October 15-16 – Gastrointestinal Drugs Advisory Committee October 17-18 – Endocrinologic and Metabolic Drugs Advisory Committee October 23-24 - Science Advisory Board to the National Center for Toxicological Research October 24 - Radiological Devices Panel of the Medical Devices Advisory Committee October 29-30 – Drug Safety and Risk Management Advisory Committee
November November 1 - Neurological Devices Panel of the Medical Devices Advisory Committee November 1-2 - Risk Communication Advisory Committee November 2 - Anti-Infective Drugs Advisory Committee November 6-7 - Oncologic Drugs Advisory Committee November 7-8 – Endocrinologic and Metabolic Drugs Advisory Committee November 7-8 -Technical Electronic Product Radiation Safety Standards Committee November 9 - Nonprescription Drugs Advisory Committee November 14 - Circulatory System Devices Panel of the Medical Devices Advisory Committee November 14-15 - Vaccines and Related Biological Products Advisory Committee November 28-29 - Anti-Infective Drugs Advisory Committee November 29 - Cellular, Tissue and Gene Therapies Advisory Committee
December December 4-5 - Blood Products Advisory Committee December 4-5 - Oncologic Drugs Advisory Committee December 5-6 - Circulatory System Devices Panel of the Medical Devices Advisory Committee December 6-7 - Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee December 7 - Anesthetic and Analgesic Drug Products Advisory Committee December 12-13 – Drug Safety and Risk Management Advisory Committee December 13-14 - Food Advisory Committee
AVH Price at posting:
15.0¢ Sentiment: Hold Disclosure: Held
